Pharmagen, Inc.
PHRX
$0.00
$0.000.00%
OTC PK
| 03/31/2014 | 12/31/2013 | 09/30/2013 | 06/30/2013 | 03/31/2013 | |
|---|---|---|---|---|---|
| Revenue | -19.85% | 12.97% | 25.60% | 143.34% | 317.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.85% | 12.97% | 25.60% | 143.34% | 317.81% |
| Cost of Revenue | -51.40% | -41.12% | -9.69% | 216.92% | 377.49% |
| Gross Profit | 31.83% | 141.09% | 86.98% | 79.75% | 246.81% |
| SG&A Expenses | 16.37% | 54.96% | 82.22% | 107.70% | 297.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.68% | 9.68% | 38.30% | 144.62% | 329.59% |
| Operating Income | -1.72% | -2.99% | -76.92% | -148.11% | -362.27% |
| Income Before Tax | -79.57% | -116.53% | -148.55% | -340.67% | -433.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.57% | -116.53% | -148.55% | -340.67% | -433.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.57% | -116.53% | -148.55% | -340.67% | -433.57% |
| EBIT | -1.72% | -2.99% | -76.92% | -148.11% | -362.27% |
| EBITDA | 1.47% | 0.18% | -76.04% | -152.17% | -388.84% |
| EPS Basic | -85.23% | -115.38% | -132.08% | -245.45% | -238.46% |
| Normalized Basic EPS | -23.21% | -48.00% | -114.71% | -242.86% | -250.00% |
| EPS Diluted | -85.23% | -115.38% | -132.08% | -245.45% | -238.46% |
| Normalized Diluted EPS | -23.21% | -48.00% | -114.71% | -242.86% | -250.00% |
| Average Basic Shares Outstanding | 9.97% | 10.65% | 22.58% | 42.63% | 68.23% |
| Average Diluted Shares Outstanding | 9.97% | 10.65% | 22.58% | 42.63% | 68.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |